ANTIMONY CATION (3+)

US Previously Marketed

First marketed in 1921

Details

Stereochemistry	ACHIRAL
Molecular Formula	Sb
Molecular Weight	121.76
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	3

SHOW SMILES / InChI

Structure Search

SMILES

[Sb+3]

InChI

InChIKey=FAWGZAFXDJGWBB-UHFFFAOYSA-N

InChI=1S/Sb/q+3

HIDE SMILES / InChI

Molecular Formula	Sb
Molecular Weight	121.76
Charge	3
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.whocc.no/atcvet/atcvet_index/?code=QR05CA07https://www.ncbi.nlm.nih.gov/pubmed/5295139 | https://www.ncbi.nlm.nih.gov/pubmed/14851220 | https://www.ncbi.nlm.nih.gov/pubmed/8898332
Curator's Comment: description was created based on several sources, including https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ef48d40-6d63-440b-a73c-46d89f425936

Stibophen (Fuadin), an organic trivalent antimony compound, has been used for many years in the treatment of schistosomiasis. Stibophen is used as treatment of schistosomiasis by intramuscular injection. Stibophen is known to act by selectively inhibiting worm PFK.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
ATP-dependent 6-phosphofructokinase 21 Target ID: Q27778 Gene ID: NA Gene Symbol: PFK Target Organism: Schistosoma mansoni (Blood fluke) Sources: https://www.ncbi.nlm.nih.gov/pubmed/8898332 \| https://www.ncbi.nlm.nih.gov/pubmed/13446367	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Schistosomiasis 32 Sources: https://www.ncbi.nlm.nih.gov/pubmed/193200 https://www.ncbi.nlm.nih.gov/pubmed/193201 https://www.ncbi.nlm.nih.gov/pubmed/13268811 https://www.ncbi.nlm.nih.gov/pubmed/20292219	Curative		Approved 8583	Fuadin Approved Use Schistosomiasis
Unknown 2596

PubMed

Title	Date	PubMed
Investigation on the pharmacological profile of 2,6-diacetylpyridine bis(benzoylhydrazone) derivatives and their antimony(III) and bismuth(III) complexes.	2012-07	22520151
Antimony impairs nucleotide excision repair: XPA and XPE as potential molecular targets.	2010-07-19	20509621
Purification, kinetics and inhibition by antimonials of recombinant phosphofructokinase from Schistosoma mansoni.	1996-10-30	8898332
[Substantiation of maximum permissible levels of antimony trioxide and pentasulide in the atmospheric air of inhabitated places].	1989-04	2744535
Current chemotherapy of schistosomiasis japonica in the Philippines.	1976-06	193200
Laboratory studies on the joint effects of certain tris (p-aminophenyl) carbonium salts and antimonials as antischistosomal drugs.	1965	5295139
Evaluation of fuadin therapy in schistosomiasis japonica.	1951-04	14851220

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Unknown

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:36:30 GMT 2025` Edited by `admin` on `Mon Mar 31 18:36:30 GMT 2025`
Record UNII	069647RPT5
Record Status	`Validated (UNII)`
Record Version